Healthcare entity

Nalbuphine ER

Technology

All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Cibus Inc, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.

Last mentioned: Mar 18, 2026

Entity pulse

Recent coverage · Nalbuphine ER

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Nalbuphine ER

All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Cibus Inc, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. Nalbuphine ER appears in 1 tracked Healthcare story from March 18, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 24 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Nalbuphine ER. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Q4 Earnings Call

    Management details strategic advances and future clinical roadmap.

  2. Data Readout

    Anticipated Phase 2b/3 data for Haduvio in chronic cough indications.

  3. Fiscal Year End

    Trevi concludes 2025 with key clinical milestones met for IPF chronic cough.

  4. Q4 Strategic Pivot

    Trevi refocuses resources on Haduvio's late-stage respiratory trials.

Stories mentioning Nalbuphine ER 1

Market Trends Neutral

Trevi Therapeutics Advances Chronic Cough Pipeline Amid Q4 Strategic Pivot

Trevi Therapeutics reported significant strategic progress in its Q4 2025 earnings, focusing on the clinical development of Haduvio for chronic cough in IPF. While the company achieves key R&D milestones, the broader biotech sector continues to navigate a complex financial landscape characterized by high capital costs and strategic realignments.

2 sources

Source: finance.yahoo.com · finance.yahoo.com

Nalbuphine ER is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.